For various reasons, most lung cancer patients have metastases of different degrees when they are diagnosed and lose the opportunity of surgery, while some patients have undergone surgery but soon have metastatic lesions in the lungs or other areas. Therefore, the importance of chemotherapy for lung cancer, as a systemic treatment method, is gaining more and more attention. So, how should lung cancer patients choose chemotherapy? Combination of Chinese and western medicine is effective. Chemotherapy drugs have certain toxicity and can damage normal cells, while if combined with Chinese medicine, it can improve the efficacy on one hand, reduce the toxic side effects of chemotherapy on the other hand, and improve the immune function of human body, so the treatment effect is better than chemotherapy alone. Combine acute treatment of symptoms and slow treatment of the root cause, and combine local and systemic treatment. Patients with lung cancer should choose different chemotherapy methods according to the systemic condition and clinical symptoms, such as interventional chemotherapy, i.e. bronchial artery or pulmonary artery intubation, if they have severe shortness of breath or hemoptysis; if they have a large amount of pleural effusion, they should adopt intrathoracic local chemotherapy after chest drainage. Intravenous chemotherapy should be preferred. Even if the tumor is relatively limited, systemic chemotherapy must be added because distant metastasis of lung cancer is more common, and systemic chemotherapy is an effective means to prevent metastasis. Treatment must be standardized, and postoperative clearance is indispensable. Many lung cancer patients’ lumps shrink significantly or even disappear after chemotherapy, but then recur or metastasize soon afterwards, one of the important reasons is that the treatment is not standardized enough. Lung cancer has different cytological types such as squamous type, glandular type and small cell undifferentiated type. The clinical stage is also different, and the drug regimen, chemotherapy method and treatment course are also different, so standardized treatment must be given. Generally speaking, small cell undifferentiated lung cancer should be treated with full epithelial chemotherapy as much as possible due to its high malignancy and early distant metastasis, and the course of treatment should be longer. For squamous and adenocarcinoma, local chemotherapy should be considered, and the course of treatment may be shorter. For postoperative lung cancer patients, there may be micro metastases that have not yet been found in the body, so for the sake of prudence, systemic chemotherapy should be administered to kill the residual cancer cells in the body, and for those with stage II or above, chemotherapy must be administered 3-4 weeks after surgery. and stage. The combination of immunotherapy and biomissile therapy is effective. Because chemotherapy drugs have a greater toxicity, some chemotherapy methods such as interventional therapy are somewhat invasive. The use of chemotherapy is somewhat limited. The combination of immunotherapy and chemotherapy, i.e. monoclonal antibodies (monoclonal antibodies for short) and anti-cancer drugs, has made up for this deficiency and greatly widened the path of anti-cancer treatment. Since monoclonal antibodies have specific guiding property, they are called biological missiles that can reach tumor tissues directly after entering the body.